Aliskiren is the first direct renin inhibitor for the treatment of hypertension. Clinical experience from studies in over 14,000 patients has shown that aliskiren, alone or in combination with other antihypertensive therapies, provides effective blood pressure lowering with a good safety and tolerability profile.The ultimate aim of antihypertensive therapy, however, is to reduce the risk of adverse cardiovascular and renal outcomes.The effect of aliskiren on surrogate markers of organ damage and clinical outcomes is being assessed in the ongoing ASPIRE HIGHER programme, the largest clinical trials programme in the cardio-renal disease area. Results from the ALOFT, AVOID and ALLAY studies suggest that aliskiren has positive effects on markers of cardiovascular and renal damage in patients with type 2 diabetes and nephropathy, heart failure and left ventricular hypertrophy.ASPIRE HIGHER also includes four large-scale studies assessing the potential outcome benefits of aliskiren, and the results of these trials will help define the clinical utility of aliskiren in the treatment of cardiovascular and renal diseases. In this article, we review the antihypertensive efficacy of aliskiren and explore its potential in the management of cardiovascular and renal risk.
Wang YR, Alexander GC, Stafford RSOutpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med2007;167:141-7.
2.
Ong KL, Cheung BM, Man YB, Lau CP, Lam KSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension2007 ;49:69-75.
3.
Editorial. Hypertension: uncontrolled and conquering the world . Lancet2007;370:539.
4.
Euroaspire IILifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J2001;22:554-72.
5.
Gradman AH, Vivas Y.New drugs for hypertension: what do they offer?Curr Hypertens Rep2006;8:425-32.
6.
Krum H., Gilbert RENovel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens2007; 25:25-35.
7.
Tigerstedt R. , Bergman P.Niere und kreislauf (kidney and circulation) . Skand Arch Physiol1898; 8:223-38.
8.
Goldblatt H. , Lynch J., Hanzel R., Summerville W.Studies of the elevation of systolic blood pressure by means of renal ischemia. J Exp Med1934;59:347-79.
9.
Atlas SA, Rosendorff C.The renin-angiotensin system - from Tigerstedt to Goldblatt to ACE inhibition and beyond. Mt Sinai J Med1998 ;65:81-6.
10.
Volpe M., Savoia C., De Paolis P., Ostrowska B., Tarasi D., Rubattu S.The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol2002;13(suppl 3): S173-8.
11.
Turnbull F.Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet2003 ; 362:1527-35.
12.
Turnbull F., Neal B., Pfeffer M. et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens2007;25:951-8.
13.
Engeli S., Negrel R., Sharma AMPhysiology and pathophysiology of the adipose tissue renin-angiotensin system . Hypertension2000;35:1270-7.
14.
Carey RM, Siragy HMNewly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev2003;24:261-71.
15.
Lavoie JL, Sigmund CDMinireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology2003;144:2179-83.
16.
Danser AH, Deinum J.Renin, prorenin and the putative (pro)renin receptor. Hypertension2005;46:1069-76.
17.
Danser AHJ , van Kesteren CA, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation1997;96:220-6.
18.
Danser AH, van den Dorpel MA, Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab1989;68:160-7.
19.
Davies L., Fulcher GR, Atkins A. et al. The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complications1999;13:45-51.
20.
Engeli S., Schling P., Gorzelniak K. et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?Int J Biochem Cell Biol2003;35:807-25.
21.
Faloia E., Gatti C., Camilloni MA et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest2002;25:309-14.
22.
Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:995-1003.
23.
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000;342:145-53.
24.
Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001;345:851-60.
25.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med1993;329:1456-62.
26.
Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
27.
Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol2004;15:3126-33.
28.
Weber MA, Giles TDInhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?Rev Cardiovasc Med2006;7:45-54.
29.
Skeggs LT, Jr., Kahn JR, Lentz K., Shumway NPThe preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med1957;106:439-53.
30.
Maibaum J., Feldman DLRenin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents2003;13:589-603.
31.
Azizi M., Webb R., Nussberger J., Hollenberg NKRenin inhibition with aliskiren: where are we now, and where are we going?J Hypertens2006;24:243-56.
32.
Menard J., Azizi M.The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens2007;25:1775-82.
33.
Gradman AH, Flack JM, Arora V. et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension. Circulation2006;114:773.
34.
Sealey JE, Laragh JHAliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens2007;20:587-97.
35.
Hollenberg NKA brief response to Sealey and Laragh. J Renin Angiotensin Aldosterone Syst2007;8:53.
36.
Kang JJ, Toma I., Sipos A., McCulloch F., Peti-Peterdi J.Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy. Adv Drug Deliv Rev2006;58:824-33.
37.
Danser AHJ , Charney A., Feldman DL, Nussberger D., Fisher ND, Hollenberg NKThe renin rise with aliskiren: it's simply stoichiometry. Hypertension2008;51:e27-8.
38.
Sica D., Andersen K., Oh BH, Arora V., Bush C., Keefe DLEffects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension. J Clin Hypertens2008;10(suppl A):A34-5P69.
39.
Oh BH, Mitchell J., Herron JR, Chung J., Khan M., Keefe DLAliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension . J Am Coll Cardiol2007;49:1157-63.
40.
Keefe DL, Andersen K., Weinberger MH et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor. J Am Coll Cardiol2007;49:372AP-1014-204.
41.
Menard J., Guyene TT, Peyrard S., Azizi M.Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens2006;24:529-34.
42.
Nussberger J., Wuerzner G., Jensen C., Brunner HRAngiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril . Hypertension2002 ;39:E1-8.
43.
Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007;67:1767-92. 44. Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int 2007;73:679-83.
44.
Van Tassell BW, Munger MAAliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother2007 ;41:456-64.
45.
Jensen C., Herold P., Brunner HRAliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov2008; 7:399-410.
46.
Staessen JA , Li Y., Richart T.Oral renin inhibitors . Lancet2006;368:1449-56.
47.
Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y., Bedigian MPAliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients . Circulation2005;111:1012-18.
48.
Kushiro T., Itakura H., Abo Y., Gotou H., Terao S., Keefe DLAliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res2006; 29:997-1005.
49.
Schmieder RE , Philipp T., Guerediaga J. et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens2007;9(suppl A):A182P-436.
50.
Andersen K. , Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens2008;26:589-99.
51.
Oparil S., Yarows SA, Patel S., Fang H., Zhang J., Satlin A.Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet2007;370:221-9.
52.
Pool JL, Schmieder RE, Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens2007;20:11-20.
53.
Stanton A., Jensen C., Nussberger J., O'Brien E.Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension2003;42:1137-43.
54.
Strasser RH, Puig JG, Farsang C., Croket M., Li J., van Ingen H.A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens2007;21:780-7.
55.
Palatini P., Jung W., Shlyakhto E., Botha J., Bheda M., Keefe DLComparative antihypertensive efficacy of the oral direct renin inhibitor aliskiren, irbesartan and ramipril after a missed dose: a double-blind ambulatory blood pressure monitoring study. J Am Coll Cardiol2008;51:A-371817-8.
56.
Weir MR, Bush C., Anderson DR, Zhang J., Keefe DL, Satlin A.Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis . J Am Soc Hypertens2007; 1:264-77.
57.
Bourgault C. , Senecal M., Brisson M., Marentette MA, Gregoire JPPersistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens2005;19:607-13.
58.
Vaidyanathan S., Jarugula V., Dieterich H-A., Howard D., Dole WPClinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet2008;47:515-31.
59.
Chobanian AV , Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension2003;42:1206-52.
60.
Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension . J Renin Angiotensin Aldosterone Syst2007 ;8:190-8.
61.
Villamil A. , Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide . J Hypertens2007 ;25:217-26.
62.
Drummond W. , Munger MA, Essop MR, Maboudian M., Khan M., Keefe DLAntihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens2007 ;9:742-50.
63.
Stergiou GS , Makris T., Papavasiliou M., Efstathiou S., Manolis A.Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens2005;23:883-9.
64.
Chrysant SG , Murray AV, Hoppe UC et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin2008;24:1039-47.
65.
Parving HH, Persson F., Lewis JB, Lewis EJ, Hollenberg NKAliskiren combined with losartan in type 2 diabetes and nephropathy . N Engl J Med2008;358:2433-46.
66.
McMurray JJV , Pitt B., Latini R. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail2008;1:17-24.
67.
Birkenhäger WH, Staessen JADual inhibition of the renin system by aliskiren and valsartan. Lancet2007;370:195-6.
68.
Perazella MADrug-induced hyperkalemia: old culprits and new offenders. Am J Med2000;109:307-14.
69.
Phillips CO , Kashani A., Ko DK, Francis G., Krumholz HMAdverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med2007;167:1930-6.
70.
Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008;358:1547-59.
71.
Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med2001;345:870-8.
72.
Jennings DL , Kalus JS, Coleman CI, Manierski C., Yee J.Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis . Diabet Med2007;24:486-93.
73.
MacKinnon M. , Shurraw S., Akbari A., Knoll GA, Jaffey J., Clark HDCombination therapy with anangiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis2006;48:8-20.
74.
Kunz R., Friedrich C., Wolbers M., Mann JFMeta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med2008;148:30-48.
75.
Kohn O.Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease. Evid Based Med2008;13:73.
76.
Latini R., Masson S., Anand I. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation2002 ;106:2454-8.
Gosse P.Left ventricular hypertrophy as a predictor of cardiovascular risk . J Hypertens Suppl2005;23:S27-33.
79.
Solomon SD, Appelbaum E., Manning WJ et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation2009;119:530-7.
80.
Lu H., Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest2008;118:984-93.
81.
Imanishi T. , Tsujioka H., Ikejima H. et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension2008 ;52:563-72.
82.
Nussberger J., Aubert JF, Bouzourene K., Pellegrin M., Hayoz D., Mazzolai L.Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension2008 ;51:1306-11.
83.
Brown MJAliskiren. Circulation2008;118:773-84.
84.
Duprez DA, Davis P., Botha J.The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients > 65 years of age with systolic hypertension. Circulation2008 ;118:S886-7.
85.
Jordan J., Engeli S., Boye SW, Le Breton S., Keefe DLDirect renin inhibition with aliskiren in obese patients with arterial hypertension . Hypertension2007;49:1047-55.
